CSPC Innovation Pharmaceutical (300765.SZ) subsidiary Wushinu Monoclonal Antibody Injection obtains drug registration certificate.

CSPC Innovation Pharmaceutical (300765.SZ) announced that its holding subsidiary CSPC PHARMA, Jus Pharma Biotechnology Co., Ltd., recently received the National Medical Products Administration's approval for the issuance of the registration certificate for the injection of ustekinumab (trade name: Enyi Ke). The announcement stated that ustekinumab is a fully human IgG1 monoclonal antibody that can bind with high affinity and specificity to the p40 protein subunits of human interleukin IL-12 and IL-23. IL-12 and IL-23 are naturally occurring cytokines that play a key role in the pathogenesis of plaque psoriasis and Crohn's disease inflammation and immune response processes. Ustekinumab works by blocking the interaction with the IL-12R 1 cell surface receptor chain, disrupting IL-12 and IL-23-mediated signaling and cytokine cascade reactions, effectively relieving disease symptoms, continuously improving the condition, and bringing long-term clinical benefits to patients.